GlassScriptPhysician profile
Michael J Nunez
NPI 1669413019
$3,944.73
in general payments reported to CMS, 2019-2025
21 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $79.23 · 2021: $437 · 2022: $752 · 2023: $593 · 2024: $823 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,492.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,494.55 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $709.47 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $667.53 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $202.48 | 2021-2022 | |
| Lilly USA, LLC | $155.64 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $130.42 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.57 | 2022-2025 | Xifaxan |
| Ferring Pharmaceuticals INC. | $105.94 | 2019-2023 | Clenpiq |
| Ironwood Pharmaceuticals, INC | $62.61 | 2019-2025 | |
| Madrigal Pharmaceuticals | $59.59 | 2025 | Rezdiffra |
| Celgene Corporation | $47.38 | 2022 | |
| Janssen Biotech, INC. | $47.10 | 2019-2024 | Stelara |
| Allergan, INC. | $27.30 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $21.14 | 2022 | |
| Redhill Biopharma INC. | $20.31 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $15.65 | 2025 | Vowst |
| Siemens Medical Solutions USA, INC. | $14.75 | 2019 | |
| Olympus America INC. | $14.48 | 2025 | Single Use Repositionable Clip |
| Alfasigma USA, INC. | $14.37 | 2020 | |
| Braintree Laboratories, INC. | $13.45 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Nunez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.